DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas

Latent Epstein-Barr virus (EBV) infection is associated with several types of cancer. Several clinical studies have targeted EBV antigens as immune therapeutic targets with limited efficacy of EBV malignancies, suggesting that additional targets might be important. BamHI-A rightward frame 1 (BARF1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xizhou, Perales-Puchalt, Alfredo, Wojtak, Krzysztof, Xu, Ziyang, Yun, Kun, Bhojnagarwala, Pratik S., Bordoloi, Devivasha, Park, Daniel H., Liaw, Kevin, Bah, Mamadou A., Lieberman, Paul M., Gary, Ebony N., Patel, Ami, Weiner, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761958/
https://www.ncbi.nlm.nih.gov/pubmed/35071745
http://dx.doi.org/10.1016/j.omto.2021.12.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761958/
https://www.ncbi.nlm.nih.gov/pubmed/35071745
http://dx.doi.org/10.1016/j.omto.2021.12.017

Ejemplares similares